SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                 ______________


                                    FORM 8-K

                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                                 ______________



       Date of Report (Date of earliest event reported): August 10, 2004
                                                         ---------------

                           Interleukin Genetics, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


     Delaware                        000-23413                   94-3123681
 -------------------               --------------            -------------------
  (State or other                   (Commission                (IRS Employer
   jurisdiction of                   File Number)            Identification No.)
   incorporation)                                                94-3123681



                      135 Beaver Street, Waltham, MA 02452
              -----------------------------------------------------
               (Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (781) 398-0700
                                                   ----------------

                                 Not Applicable
         ---------------------------------------------------------------
          (Former name or former address, if changed since last report)





Item 12. Disclosure of Results of Operations and Financial Condition.

The following exhibits are furnished with this report:

Exhibit Number                      Description
--------------                      -----------

99.1                                Press Release dated August 10, 2004

     On August 10, 2004, the Registrant issued a press release to report its
financial results for the quarter ended June 30, 2004. A copy of the press
release is attached to this current report on Form 8-K as Exhibit 99.1.





                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                                      Interleukin Genetics, Inc.
                                                      --------------------------
                                                      (Registrant)



Date: August 10, 2004                                 /s/ Fenel M. Eloi
                                                      --------------------------
                                                      Fenel M. Eloi
                                                      Chief Operating Officer,
                                                      Chief Financial Officer,
                                                      Treasurer and Secretary